利福昔明-金双歧序贯治疗腹泻型肠易激综合征临床观察

目的 观察利福昔明-金双歧序贯疗法治疗腹泻型肠易激综合征疗效.方法 80例IBS-D病人按照随机原则分为A组（利福昔明-金双歧序贯组）、B组（益生菌组）、C组（对照组）治疗,疗程均4周,记录治疗前后患者胃肠道主要症状评分.统计分析采用SPSS17.0软件,P＜0.05为差异有统计学意义.结果 治疗4周后,A组患者较同组治疗前及C组同期腹痛、腹胀程度和频度、排便次数及大便性状和总评分均显著下降（P＜0.05）,具有统计学意义;A组较B组同期腹痛程度和频度、腹胀程度、排便次数及大便性状和总评分均显著下降（P＜0.05）,具有统计学意义.B组患者治疗后腹痛程度和频度、腹胀频度、大便性状及总评分显著下降（P＜0.05）,具有统计学意义.C组患者治疗后症状评分下降不明显（P＞0.05）.结论 利福昔明-金双歧序贯治疗腹泻型肠易激综合征有效,可有效改善临床症状,且作用优于单用益生菌治疗,值得临床推广应用.

The effects of sequential treatment with Rifaximin-Golden bifid on patients with diarrhea-predominant irritable bowel syndrome

Objective To evaluate the effects of sequential treatment with Rifaximin-Golden bifid on patients with di- arrhea-predominant irritable bowel syndrome （IBS-D）. Methods Eighty patients with definite IBS-D were randomly di- vided into 3 groups： Group A（Rifaximin-Golden bifid sequential treatment group） , group B（Probiotics treatment group） and group C （control group）. The gastro-intestinal symptoms were scored before and after the treatments during the whole treatment period （four weeks）. Statistical analysis was performed using SPSS17.0 software package. Significance was set at P〈0.05. Results Compared with patients before treatment and in the group C,the symptom scores in the de- gree and frequency of abdominal pain and abdominal distension , stool frequency, stool consistency, and the total score of group A was decreased significantly （P 〈0. 05）. Compared with patients in the group B ,the symptom scores in the degree and frequency of abdominal pain, the degree of abdominal distension, stool frequency, stool consistency, and the total score of group A was decreased significantly （P 〈0.05）. The symptom scores in the degree and frequency of ab- dominal pain, the frequency of abdominal distension, abnormal defecation, and the total score of group B were signifi- cantly decreased （P 〈0. 05）, than those scores before treatment. In group C, symptom Scores that after treatment have decreased, but the differences were not significant （P 〉0.05）. Conclusion Rifaximin-Golden bifid sequential treatment is effective to improve symptoms for the IBS-D patients.